Aarti Pharmalabs Limited
Incorporated in 2019, Aarti Pharmalabs Ltd is a manufacturer of Pharmaceuticals and Nutraceuticals
What Aarti files
- Others55
- Investor Meet29
- Updates11
- Board Meeting10
- Important10
- Dividend/Bonus9
Aarti Pharmalabs (APL) reported a strong Q1 FY27, with consolidated operational revenue rising 38.7% YoY to ₹535.8 Cr. Consolidated PAT surged 65.4% YoY to ₹76.1 Cr, and diluted EPS grew 65.2% to ₹8.39. Xanthine Derivatives (57% of revenue) and International markets (60% of sales) were key growth contributors. The company...
Aarti Pharmalabs closed FY26 with standalone revenue of ₹1,797.6 Cr, a modest 1.5% YoY rise. However, profit after tax (PAT) saw a 31.5% decline to ₹176.2 Cr, with diluted EPS at ₹19.42. International sales contributed 54% of the year's revenue. Strategic growth is driven by significant capacity expansions. Xanthine derivatives...
Aarti Pharmalabs reported Q3 FY26 operational revenue of 425.3 Cr, a 9.7% decline year-over-year. Net profit fell 40.4% YoY to 43.8 Cr, with diluted EPS at 4.83. For 9M FY26, revenue was 1217.9 Cr, a 1.9% YoY drop, and profit was 126 Cr, down 25.2% YoY. Xanthine derivatives contributed almost...
Aarti Pharmalabs, a leader in generic APIs, Xanthine derivatives, and CDMO/CMO services, reported resilient performance. For H1-FY26, standalone revenue grew 2.8% year-over-year to INR 792.6 Cr, with EBITDA at INR 169.2 Cr (+0.5% YoY). However, PAT saw a 13.6% decline to INR 82.1 Cr. Q2-FY26 standalone revenue rose 10.6% YoY...
Aarti Pharmalabs, a key player in generic APIs, Xanthine derivatives (boasting 15-20% global market share), and CDMO/CMO services, shows robust performance. For FY25, international sales contributed 52%, balancing the domestic market. The company is strategically expanding, evidenced by a new R&D center, enhanced Xanthine capacity to 5,000 TPA, and a...